Diabetic Foot Ulcer Clinical Trial
Official title:
EPC Silver Wound Gel (EPC-123) Feasibility Clinical Study: Prospective, Single-arm, Repeated Measures Study of EPC Silver Wound Gel in the Management of Locally Infected Diabetic Foot Ulcers
Verified date | January 2023 |
Source | Exciton Technologies Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this single-arm feasibility study is to investigate the safety and impact of the topical EPC Silver Wound Gel (EPC-123) in the management of diabetic foot ulcer wounds not progressing under the current standard of care.
Status | Completed |
Enrollment | 5 |
Est. completion date | September 21, 2023 |
Est. primary completion date | September 21, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosed with diabetes mellitus according to definitions outlined by the American Diabetes Association - Presenting with an active or current foot ulcer that has been identified as stalled or persistent non-healing under current standard-of-care; showing no progression in 2 weeks as per IDSA guidelines. - Presenting with a localized mild or local infection of the ulcer as listed in the IWGDF/IDSA Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections (Table 1); exceeding 0.5 cm2 in area after appropriate debridement. - Subject must agree to adhere to all protocol procedures and must be willing and able to provide written informed consent. - Correction or optimization of underlying medical problems (e.g. diabetes or systemic infection). Exclusion Criteria: - Participants exhibiting extensive gangrene, and/or immediately limb-threatening infection - Indications of osteomyelitis identified by plain radiographs taken within 2 days prior to study entry. - No palpable dorsalis pedis or posterior tibial pulse or a pedal systolic pressure (Doppler ultrasound) of = 40 mm Hg - Clinically significant peripheral arterial disease requiring vascular intervention - Patients requiring renal dialysis, immunosuppressive mediation, or those with uncontrolled hypertension. - Lymphangitis; spread beneath the fascia; muscle, joint, or bone involvement. - IDSA-defined severe infection, including systemic toxicity or metabolic instability - Current use of enzymatic debridement. - Participants with known silver sensitivity |
Country | Name | City | State |
---|---|---|---|
Canada | Lawson Health Research Institute | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Exciton Technologies Inc. |
Canada,
Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020 Mar 24;13(1):16. doi: 10.1186/s13047-020-00383-2. — View Citation
Blome C, Baade K, Debus ES, Price P, Augustin M. The "Wound-QoL": a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen. 2014 Jul-Aug;22(4):504-14. doi: 10.1111/wrr.12193. — View Citation
Boulton AJM, Armstrong DG, Hardman MJ, Malone M, Embil JM, Attinger CE, Lipsky BA, Aragon-Sanchez J, Li HK, Schultz G, Kirsner RS. Diagnosis and Management of Diabetic Foot Infections. Arlington (VA): American Diabetes Association; 2020 Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK554227/ — View Citation
Houghton PE, Kincaid CB, Campbell KE, Woodbury MG, Keast DH. Photographic assessment of the appearance of chronic pressure and leg ulcers. Ostomy Wound Manage. 2000 Apr;46(4):20-6, 28-30. — View Citation
Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346. — View Citation
Lipsky BA, Polis AB, Lantz KC, Norquist JM, Abramson MA. The value of a wound score for diabetic foot infections in predicting treatment outcome: a prospective analysis from the SIDESTEP trial. Wound Repair Regen. 2009 Sep-Oct;17(5):671-7. doi: 10.1111/j.1524-475X.2009.00521.x. Epub 2009 Aug 11. — View Citation
Lipsky BA, Senneville E, Abbas ZG, Aragon-Sanchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, van Asten SA, Urbancic-Rovan V, Peters EJG; International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280. doi: 10.1002/dmrr.3280. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of intervention-related adverse events collected throughout the trial | Clinical and/or biological adverse events will be reported over the intervention period. Severity of any adverse events will be graded. | Up to 28 days | |
Secondary | Qualitative improvement in quality of life assessment during the intervention period compared with screening period under standard of care. | Quality of life will be assessed using the qualitative "Wound QoL" tool during the intervention period compared with qualitative assessment at baseline. | Up to 28 days | |
Secondary | Progression of the Infectious Diseases Society of America and International Working Group on the Diabetic Foot Classifications of Diabetic Foot Infection during the intervention period compared with screening period under standard of care. | Progressions of PEDIS (grade 1 = no symptoms or signs of infection; to grade 4, local infection with the signs of systemic inflammatory response syndrome) or IDSA Infection Severity (Uninfected; to Severe) during the intervention period compared with screening period under standard of care. | Up to 42 days | |
Secondary | Progression the Diabetic Foot Infection (DFI) Wound Score during the intervention period compared with screening period under standard of care. | Signs and symptoms of infection will be assessed using the 10-item DFI Wound Score system inclusive of semi-quantitative measurement of purulent discharge, non-purulent discharge, erythema, induration, tenderness, pain, warmth, size, depth, undermining. The DFI Wound Score ranges from a score of 3 (less severe wound) to 49 (more severe wound). Rate of change in DFI score during the intervention period will be compared with screening period under standard of care. | Up to 42 days | |
Secondary | Progression the Bioburden Assessment Tool (BAT) during the intervention period compared with screening period under standard of care. | The degree of bioburden will be assessed using BAT; measuring for the presence or absence of signs and symptoms of infection and bioburden and subsequent clinical interpretation. Progressions of the level of bioburden risk, from Category I (colonized: at risk) to Category VI (systemic infection), during the intervention period will be compared with screening period under standard of care. | Up to 42 days | |
Secondary | Early clinical response | Quantitation of lesion erythema area and wound area at 48-72 hours following the first intervention application. | Within 48-72 hours of first intervention application | |
Secondary | Number of participants with systemic antibiotic or antifungal drug administration over the course of the intervention versus screening and baseline. | Report on the number of participants receiving administration of systemic antibiotic or antifungal drugs during the intervention period compared with screening period under standard of care. | Up to 42 days | |
Secondary | Progression in the absolute number of critical or qualified pathogen species present within the wound microbiome over the course of the intervention versus screening and baseline. | Progression in the absolute number of critical or qualified pathogens (inclusive of those pathogens identified by the Centre for Disease Control and Prevention, World Health Organization, and the FDA as per 79 FR 32464) as per gene pyrosequencing over the course of intervention versus screening and baseline. | Up to 42 days | |
Secondary | Progression in the relative quantity of critical or qualified pathogens versus commensal organisms present within the wound microbiome over the course of the intervention versus screening and baseline. | Progression in the relative composition of critical or qualified pathogens (inclusive of those pathogens identified by the Centre for Disease Control and Prevention, World Health Organization, and the FDA as per 79 FR 32464) versus commensal organisms in the wound microbiome of as per gene pyrosequencing over the course of intervention versus screening and baseline. | Up to 42 days | |
Secondary | Progression in wound microbiome over the course of the intervention versus screening and baseline. | Progression of the wound microbiome on a whole ecology basis as per gene pyrosequencing; evaluating for community membership, structure, and diversity over the course of intervention versus screening and baseline. | Up to 42 days | |
Secondary | Percent change in wound area and volume during the intervention period compared to baseline. | Percent change in wound volume (cm3) at each visit compared to baseline. | Up to 28 days | |
Secondary | Rate of wound closure, specifically percent change in area, during the intervention period compared with screening period under standard of care. | Rate of wound closure, change in wound area (cm2), over the course of the intervention period compared to the screening period. | Up to 42 days | |
Secondary | Rate of wound closure, specifically percent change in volume, during the intervention period compared with screening period under standard of care. | Rate of wound closure, change in wound volume (cm3), over the course of the intervention period compared to the screening period. | Up to 42 days | |
Secondary | Qualitative evaluation of patient satisfaction via questionnaire. | Patient satisfaction over the course of the intervention period will evaluated. Patient satisfaction of the performance of the intervention will be evaluated within a rating scale of "poor" through to "excellent". | Up to 28 days | |
Secondary | Qualitative evaluation of clinician satisfaction via questionnaire. | Clinician satisfaction over the course of the intervention period will evaluated. Clinician satisfaction of the performance of the intervention will be evaluated within a rating scale of "poor" through to "excellent". | Up to 28 days | |
Secondary | Progression of systemic biomarker C-Reactive protein (CRP). | Quantitation of clinical change in CRP (mg/L) from baseline to end of intervention period. | Up to 28 days | |
Secondary | Progression of systemic biomarker Erythrocyte sedimentation rate (ESR). | Quantitation of clinical change in ESR (mm/hr) from baseline to end of intervention period. | Up to 28 days | |
Secondary | Progression of systemic biomarker CBC and Differential. | Quantitation of clinical change in CBC and Differential (cells per cubic millimeter) from baseline to end of intervention period. | Up to 28 days | |
Secondary | Progression of systemic biomarker body temperature. | Quantitation of clinical change in body temperature (degree Celsius) over the course of the intervention versus screening and baseline. | Up to 42 days | |
Secondary | Progression in peri-wound microbiome over the course of the intervention versus screening and baseline. | Progression of the peri-wound microbiome on a whole ecology basis as per gene pyrosequencing; evaluating for community membership, structure, and diversity over the course of intervention versus screening and baseline. | Up to 42 days | |
Secondary | Quantitative progression of local inflammatory biomarkers over the course of the intervention versus screening and baseline. | Quantitation of host inflammatory cytokines and chemokines (pg/ml) inclusive of: IL-1, IL-6, IL-8, IL-10 TNF-a, MMP-8, MMP-9, MMP-2, TIMP1, and TIMP2; within the wound over the course of the intervention versus screening and baseline. | Up to 42 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauzeā¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |